chrisvoncsefalvay/vaers-outcomes huggingface dataset:
One thing after another/problems; was getting angry; Bad abdominal pain after first dose; This spontaneous case was reported by a consumer and describes the occurrence of ABDOMINAL PAIN (Bad abdominal pain after first dose), VACCINATION COMPLICATION (One thing after another/problems) and ANGER (was getting angry) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037KZOA) for COVID-19 vaccination.     The patient's past medical history included COVID-19 (had COVID in January.) in January 2021 and Hair loss (The patient noticed hair started falling off when she brushes it.).    On 08-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Mar-2021, the patient experienced ABDOMINAL PAIN (Bad abdominal pain after first dose). On an unknown date, the patient experienced VACCINATION COMPLICATION (One thing after another/problems) and ANGER (was getting angry). At the time of the report, ABDOMINAL PAIN (Bad abdominal pain after first dose), VACCINATION COMPLICATION (One thing after another/problems) and ANGER (was getting angry) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The patient stated that she was on lot of concomitant medications but declined to mention any of them. No treatment information was provided.   This case was linked to MOD-2021-090544 (Patient Link).   Reporter did not allow further contact   Most recent FOLLOW-UP information incorporated above includes: On 27-May-2021: Follow-up information received on 27 May 2021 added a new event. On 03-Aug-2021: Significant follow-up: Event added.
ACUTE RESPIRATORY FAILURE 3/17/2023  &    2/1/2023  --  RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
This spontaneous report as received from a Nurse refers to an unspecified number of patients of unknown age and gender. On an unknown date the patients were vaccinated with (Oka/Merck) VARIVAX (Lot#: J009987, Expiry: 12-AUG-2015), 0.5 ml, subcutaneous, which was improperly stored. No adverse effects were reported. No product quality complaint was involved. This case is one of the several cases linked with the same reporter link. No additional information provided. Additional information has been requested.
Patient voiced having metallic taste in mouth and had mild redness on chest and stated chest felt warm.  Patient denied any itching.
Painful tingling bilateral hands and feet x3 days. Better date of visit 3rd HPV. Associated symptoms include no numbness - Treatments tried none. Contact clinic if no improvement
Patient began  vomiting about 4 minutes after getting  his second dose of the covid-19 vaccine. Patient was instructed to have a seat. Within about 5 minutes he said he was ok. He stayed around for about 15 more minutes and said he was ok to go home.
Chills, fever, mild diarreah, fatigue, weakness in arms and legs, loss of balance, unsteady. Took Tylenol extra strength, fever and chills subsided.
The report was first received from a practice manager on 07-SEP-2018, and it was recognized as non-valid because report did not obtain any patient identify. Follow-up information has been received from the practice manager on 18-SEP-2018. This spontaneous report refers to a patient of unknown age and gender. Information of concurrent condition, medical history and concomitant therapy was not provided. On 14-AUG-2018, the patient was vaccinated with an improperly stored dose of RECOMBIVAX HB (Thimerosal free) (lot # R006746 and expiration date 19-NOV-2020) intramuscularly for prophylaxis. The sterile diluent (MERCK) (lot# and expiration date were unknown) was properly stored. No adverse event was reported. The excursion temperature on 08-NOV-2017, 16-NOV-2017, 23-JAN-2018, 06-JUN-2018, 03-JUL-2018 and 14-AUG-2018 was 47 degree Celsius for maximize 15 hours. The excursion temperature on 07-DEC-2017 was 50 degree Celsius for maximize 8.75 hours. The call was not because of data logger. This is one of several reports received from the same reporter. Sender's Comments: US-009507513-1810USA001951: US-009507513-1810USA001952: US-009507513-1810USA001953: US-009507513-1810USA001954: US-009507513-1810USA001955: US-009507513-1810USA001956: US-009507513-1810USA001957: US-009507513-1810USA001958: US-009507513-1810USA001959.
On 11/11/2000, the patient developed "chickenpox all over". In follow up, the nurse practitioner reported that on 11/11/2000 the patient experienced nasal congestion, "clear coryza" and developed raised red papules and blisters scattered over the trunk, head and extremities, also in mouth and tongue. The nurse practitioner reported that the patient recovered from his experiences. Unspecified medical attention was sought. No further information is available.
Residual numbness in my cheeks; This spontaneous case was reported by a consumer and describes the occurrence of HYPOAESTHESIA (Residual numbness in my cheeks) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced HYPOAESTHESIA (Residual numbness in my cheeks). At the time of the report, HYPOAESTHESIA (Residual numbness in my cheeks) outcome was unknown.            No concomitant medication were provided by reporter. No treatment details were provided by reporter.
Bruises all over legs.   Bruising continues today Monday March 8 with new bruises from March 7 from slight pressure on knees.    Concerned about immune thrombocytopenia reports being linked to the vaccine.
got sick and could not make it to the appointment date.; This is a spontaneous report from a contactable consumer or other non-hcp (patient himself). A male patient of an unspecified age received bnt162b2 (BNT162B2, Formulation: Solution for injection) via an unspecified route of administration on 14Jul2021 (Lot number and expiry date was not reported) as dose 1, single for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. On an unspecified date, after the first COVID-19 vaccine, the patient got sick and could not make it to the appointment date of second dose. He was supposed to get the second dose of the vaccine on 04Aug2021. The outcome of the event was unknown.  Information about lot/batch number has been requested.
This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a female patient who received Influenza vaccine for prophylaxis. On an unknown date, the patient received Influenza vaccine at an unknown dose. On an unknown date, immediately after receiving Influenza vaccine, the patient experienced injection site pain. On an unknown date, the outcome of the injection site pain was unknown. It was unknown if the reporter considered the injection site pain to be related to Influenza vaccine. Additional details were reported as follows: The age at vaccination was not reported. The patient always gets the flu vaccine and it only hurts a little. The reporter did not consent to follow up. This case has been linked with the case US2019006866, reported for same patient.
Three days after the vaccine , I experienced (more than mild)dizziness. Sluggish energy level, enough so,that Icould not go to my part time job. I went back to bed and slept off and on the rest of the day.
In November I had an A-fib episode that did not last very long, about a day or two. I made an appointment to see my Electrophysiologist who ran a twenty-four hour Holter monitor, an ultrasound of my aorta. Persantine stress test. I am currently awaiting the results of all the test. My doctor has chosen to keep me on the current strength and dosage of all medications.
elevated BP, Flushing, dyspnea, dizziness, Nausea
Patient presented to ED with fever, vomiting.  Found to have elevated troponins with myocarditis.  ECHO was normal, treated with indomethacin and colchicine and will follow up with Cardiology in a couple of weeks.
Pt recvd MMR vax; 2 wks later, lab tests revealed non-protective antibody titers to MMR;
Dizziness; Head spinning feeling; Blood pressure "skyrocketed"; Sore arm at injection site; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE PAIN (Sore arm at injection site), VERTIGO (Head spinning feeling), HYPERTENSION (Blood pressure "skyrocketed") and DIZZINESS (Dizziness) in an 88-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided by reporter.  Concomitant products included METOPROLOL, CLOPIDOGREL BISULFATE (PLAVIX), ACETYLSALICYLIC ACID (BABY ASPIRIN), ATORVASTATIN CALCIUM (LIPITOR) and LOSARTAN for an unknown indication.    On 17-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 18-Feb-2021, the patient experienced INJECTION SITE PAIN (Sore arm at injection site). On 19-Feb-2021, the patient experienced VERTIGO (Head spinning feeling) and HYPERTENSION (Blood pressure "skyrocketed"). On 20-Feb-2021, the patient experienced DIZZINESS (Dizziness). At the time of the report, INJECTION SITE PAIN (Sore arm at injection site), VERTIGO (Head spinning feeling) and HYPERTENSION (Blood pressure "skyrocketed") outcome was unknown and DIZZINESS (Dizziness) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications also included Cataract eye drops. No treatment medications were provided by reporter.
On 7/16/21, patient's mother requesting to get first dose of Moderna vaccine for her child.  Intern consulted patient and I supervised the administration of vaccine after briefly reviewing the consent form.  I must have overlooked the date of birth and focused on all the questions on form and COVID screening questionnaire.  I did not remember the patient but I must have reviewed the form as I signed on it after intern's initials.     The error was not caught until the prescription was processed.    I immediately contacted mom, and explained the situation.  She was not aware that EUA has not approved for age 12 and up.  I suggested contacting Dr and monitored the approval status of Moderna vaccine before having patient return for second dose 4 weeks later.  Mom said patient has been feeling good after the vaccine.  Dr was contacted but will be out of office until 7/21.  Mother is notified.
Prolonged, excessive irritability & screaming spells, fever & local reaction injection site lasting greater than 72 hrs. Similar reaction after initial vaccine series lasting 1-2 weeks (by parental history).
Vaccine given 3-8-10. No temp. Complained first time pain 3-16-10. X Ray, lab work, MRI - Ortho consult. (Detailed medical records upon request). "Pt arm felt like concrete" right after injection.
Boostrix was ordered for the patient. This RN administered the Boostrix per MD orders. No adverse events observed or reported at this time.
a patient that received the 1st dose of Shingrix back in 2019 hadn't received the 2nd dose yet.; This non-serious case was reported by a other health professional via call center representative and described the occurrence of incomplete course of vaccination in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received in 2019).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced incomplete course of vaccination (Verbatim: a patient that received the 1st dose of Shingrix back in 2019 hadn't received the 2nd dose yet.). The outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK Receipt Date: 19-OCT-2023 The pharmacy intern called to inform that a patient that received the 1st dose of Shingrix back in 2019 hadn't received the 2nd dose yet. Till the time of reporting, the patient did not receive the 2nd dose, which led to incomplete course of vaccination. The vaccine administration facility is the same as primary reporter for the 1st dose. The reporter consented to follow up.
Information has been received from the mother of a 22 year old female, via a consumer (friend), who on approximately 24-JAN-2007 was vaccinated in the buttock with the first dose of HPV vaccine. On approximately 24-JAN-2007 the patient developed an initial rash at the injection site, which went away.  A few days later, approximately 27-JAN-2007 the patient developed a rash on her entire trunk, spreading form her crotch to her shoulders.  The patient's mother was thought to be a nurse, who administered the injection to her daughter at home after she picked up the vaccine from her daughter's physician. It was also reported that the mother of the patient had picture of her daughter's rash. At the time of the report the patient had not recovered from the rash on her trunk.  The patient sought unspecified medical attention.  Additional information has been requested.
pt recv vax 14JAN97 & exp systemic rash & fever up to 39.5 degrees;
Pt was waiting in the post-vaccine holding area when she began c/o itchy throat and coughing at 14:14. Pt's vitals were taken and 25 mg of Benadryl administered at 14:17. Pt monitored for 1 hour. Symptoms subsided. Pt dismissed at 1510. Final vitals: BP - 110/72, HR - 64, R - 20
Itching and hives approximately 2 hours post vaccine administration. ,  Bendaryl  25 mg IM was given. Additional 30 minutes observation done. Vitals assessed. Itching subsided.
This case was reported by a pharmacist via call center representative and described the occurrence of injection site nodule in a male patient who received FLUARIX. On an unknown date, the patient received FLUARIX .5 ml. On an unknown date, an unknown time after receiving FLUARIX, the patient experienced injection site nodule. On an unknown date, the outcome of the injection site nodule was unknown. It was unknown if the reporter considered the injection site nodule to be related to FLUARIX. Additional details provide were as follows: The patient experienced hard bubble underneath the injection site. The reporter mentioned that, the patient was not concerned. The reporter did not have the patient's birthdate, lot number and expiration date.
fainting; dizzy; tachycardia; high blood pressure; then numbness to left side of face swelling then progressed to left arm left leg with excessive pressure to head; then numbness to left side of face swelling then progressed to left arm left leg with excessive pressure to head; then numbness to left side of face swelling then progressed to left arm left leg with excessive pressure to head; then numbness to left side of face swelling then progressed to left arm left leg with excessive pressure to head; This is a spontaneous report received from a contactable nurse (patient). A 52-year-old female patient received the first dose of  BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), intramuscularly on 12Mar2021 at 09:30 (at the age of 52 years) at a single dose in the left arm for COVID-19 immunization. The patient medical history and concomitant medications were not reported. The patient had no allergies to medications, food, or other products. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient was not diagnosed with COVID-19 prior to vaccination. The patient was not pregnant at the time of vaccination. On 12Mar2021, the symptoms the patient had were fainting, feeling dizzy, tachycardia, high blood pressure, then numbness to left side of face swelling then progressed to left arm left leg with excessive pressure to head. The events resulted to doctor or other healthcare professional office/clinic visit and Emergency room/department or urgent care. The patient did not receive any treatment for the events (as reported). Since the vaccination, the patient has not been tested for COVID-19. The outcome of the events was recovered with sequel in Mar2021.  Information on the lot/batch number has been requested.; Sender's Comments: A contributory role of BNT162B2 to event fainting cannot be excluded based on temporal association. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.
High ferritin level of 556.2 ng/ml  from acute-phase protein response to vaccine. Have been iron deficient since 2012. Get yearly infusion. Lab test on 4/15/22 and results on 4/22/22. Had headaches, lethargy, joint pain . Now lethargy. Have not been retested yet.
Patient was fully vaccinated. Hospitalized and died due to COVID-19. She presented to the ER "acute onset shortness of breath with apparent hypoxia at home 45% on room air." The reason for admission was "Respiratory failure with hypoxia." Both of these statements were due respiratory distress from Covid-19.
Patient said he developed a rash on parts of his body. Pharmacist on duty on 1/11/21 recommended benadryl topical to the patient
No additional AE information; dose of Proquad administered to an adult; This spontaneous report was received from a pharmacy student referring to an adult patient of unknown gender. No patient's pertinent medical history, concurrent conditions, drug reactions or allergies, nor concomitant therapies were reported.      On 22-MAR-2022, the adult patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live(PROQUAD) lot # U016976, expiration date 24-NOV-2022, 0.5 milliliter, once, (route, anatomical location, and dose number were not reported), as prophylaxis (product administered to patient of inappropriate age). No additional adverse event was reported.
Information has been received from a consumer concerning his daughter who in approximately 1998 was vaccinated with a dose of varicella virus vaccine live. Subsequently, in approximately July 2000, the patient developed a slight case of chickenpox. It was reported that the patient's sister had a similar experience following exposure to varicella virus vaccine live. Additional information has been requested
This spontaneous report as received from a pharmacist refers to a patient of unknown age and gender. On 25-AUG-2015, the patient was vaccinated with a dose of ZOSTAVAX (dose, route, lot # and expiration date were not provided). On 27-AUG-2015, the patient presented at the pharmacy with a prescription of MEDROL DOSEPAK. The reason for MEDROL DOSEPAK was needed was unknown. The outcome of the unspecified adverse event was unknown. Additional information has been requested.
I have felt an itch mainly in the arm where I was injected; As the times passes I feel it in various parts of the body.; Tingling in the legs; Joint pain; Headache; This is a spontaneous report from a contactable consumer (patient herself). A 22-years-old female patient received BNT162B2 (COMIRNATY, Formulation: Solution for injection, Lot number: EW0179, Expiry date: Unknown), via an unspecified route of administration in Arm Left on 04May2021 13:15 as dose 2, single (at the age of 22-years-old) for COVID-19 immunisation. The patient was not pregnant at the time of vaccination. The patient was not diagnosed with COVID-19 prior to vaccination. Since the vaccination, the patient was not tested for COVID-19. The patient did not receive any other vaccine within 4 weeks prior to the COVID-19 vaccine. The most recent COVID-19 vaccine was administered in Hospital. The patient's medical history included thyroid disorder and seafood allergy from an unknown date and unknown if ongoing. Concomitant medication included levothyroxine sodium (SYNTHROID 75 and SYNTHROID 88) taken for an unspecified indication, start and stop date were not reported. The patient previously received past drug BNT162B2 (COMIRNATY, Formulation: Solution for injection, Lot number: EW0161, Expiry date: Unknown), via an unspecified route of administration in Arm Left on 13Apr2021 10:15 as dose 1, single for COVID-19 immunisation. On 04May2021 14:00, after a couple of hours, the patient experienced that she had felt an itch mainly in the arm where she was injected, as the times passed, she felt it in various parts of the body, tingling in the legs, joint pain and headache. Therapeutic measures were not taken as a result of adverse events. The outcome of the events was unknown.   No follow-up attempts are needed. No further information is expected.
swelling in the left foot which went down the next morning; a "burning feeling" in the back of her left arm from just above the elbow to her chest; pain is a surface level pain and has remain consistent from the evening of the vaccination until today 9/22/2021; This is a spontaneous report received from a contactable reporter(s) (Pharmacist).  A 48 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 01Sep2021 (Lot number: fc9182) at the age of 48 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Diabetes" (unspecified if ongoing), notes: Diabetes; "tachycardia" (unspecified if ongoing), notes: tachycardia. Concomitant medication(s) included: METFORMIN; GLIPIZIDE; METOPROLOL; TRULICITY. Past drug history included: Vancomycin, reaction(s): "hives", notes: known allergies: Vancomycin (hives); Vancomycin, reaction(s): "known allergies: Vancomycin", notes: known allergies: Vancomycin (hives). The following information was reported: PERIPHERAL SWELLING (non-serious) with onset 01Sep2021, outcome "recovered" (02Sep2021), described as "swelling in the left foot which went down the next morning"; BURNING SENSATION (non-serious) with onset 01Sep2021, outcome "not recovered", described as "a "burning feeling" in the back of her left arm from just above the elbow to her chest"; PAIN (non-serious) with onset 01Sep2021, outcome "not recovered", described as "pain is a surface level pain and has remain consistent from the evening of the vaccination until today 9/22/2021". The events "swelling in the left foot which went down the next morning", "a "burning feeling" in the back of her left arm from just above the elbow to her chest" and "pain is a surface level pain and has remain consistent from the evening of the vaccination until today 9/22/2021" were evaluated at the physician office visit. Therapeutic measures were not taken as a result of peripheral swelling, burning sensation. Therapeutic measures were taken as a result of pain.  No follow-up attempts are possible. No further information is expected.
Cold sweats, hot flashes, nausea, body ache, dizziness, fatigue, nerve pain (finger tips and toes) painful upon touch.
INJECTION SITE REACTION THAT OCCURRED ABOUT 6 INCHES BELOW THE INJECTION SITE - REDNESS, SWELLING, NODULE UNDER THE SKIN - CLEARING UP EACH DAY. AS OF TODAY 1.25.19 THE SWELLING IS GONE, THE AREA IS LIGHT PINK, & THE NODULE IS ALMOST GONE.
Patient was given pediatric dose (0.2 ml) instead of standard dose (0.3 ml)  for 12-15 year old's.
Achy, weak legs.  Kept me up 2-3 hrs. during the first night.  Symptoms have continued daily since my shot and am having trouble doing every day things.  My arms were very weak the first 2-3 weeks, some still remains.  Main concern is my legs.  Walking, sitting, standing all cause weakness. I am going to contact my physician again on Monday to see what recourse they can take to somehow correct the physical problems I am having.